Trial of tivanisiran for dry eye associated with Sjögren’s fails to meet primary endpoint

Fact checked byChristine Klimanskis, ELS

Key takeaways:

The trial evaluated the efficacy of tivanisiran in dry eye associated with Sjögren’s syndrome.
More than 200 patients were evaluated in the United States and Spain.

A phase 3 clinical trial of tivanisiran failed to meet the primary endpoint in the treatment of dry eye disease associated with Sjögren’s syndrome, according to a press release from Sylentis.

The primary endpoint of the randomized, double-masked, placebo-controlled trial was the evaluation of tivanisiran’s efficacy, including signs and symptoms.

Generic Breaking News infographic — A phase 3 clinical trial of tivanisiran failed to meet the primary endpoint in the treatment of dry eye disease associated with Sjögren’s syndrome, according to a press release from Sylentis.

Tivanisiran is based on RNA interference and administered as preservative-free eye drops. The drug selectively inhibits production of the transient receptor potential cation channel, which mediates transmission of ocular pain, according to the release.

The trial took place at more than 40 hospitals in the United States and eight in Spain and comprised 203 patients.

Published by:

Sources/Disclosures

Collapse

Source:

Press Release

Read more

Trial of tivanisiran for dry eye associated with Sjögren’s fails to meet primary endpoint

Key takeaways:

Related Content